On the second heterologous vaccine doses "we must be more than calm".
Dg Aifa,
Nicola Magrini
, told Rainews24
.
"In the decisions taken in this phase of the pandemic, less heavy than a few weeks ago, the choice was made - he explained - to avoid that in this phase young populations are potentially offered vaccines that have a very remote risk of a serious event, and therefore safety has been privileged to guarantee maximum safe vaccines for all ".
It is a "choice also shared by several countries, so I believe that trust and maximum tranquility is the message to be given".
At the basis of the heterolog vaccination, he continued, "there are clinical studies that were done with the utmost ethical rigor, but they were not particularly problematic studies. The question was whether there would be more undesirable effects and to what extent, and they are mostly mild or moderate effects, and therefore the safety with regard to administration is very high ".
Compared to whether the AstraZeneca and J&J vaccines have the same positioning, he concluded, "an additional space has been left for J&J regarding the fact that side effects seem less frequent, much less, and therefore in the accumulation of data in the world we will see if this vaccine, which is simpler in single doses, can somehow be recovered for special populations in total safety ".